and increases the risk of HIV transmission [2] . N. gonorrhoeae develops antimicrobial resistance through a variety of molecular mechanisms [3] [4] [5] [6] . Penicillinase-producing N. gonorrhoeae was first identified in the United States in 1976, and by 1987, penicillin was no longer recommended for treatment of gonorrhea [7, 8] . Resistance to tetracyclines developed throughout the 1970s and 1980s. High rates of fluoroquinolone-resistant N. gonorrhoeae (QRNG) have been identified in southeast Asia and the Pacific Islands, including Hawaii [9] . Before 2000, only sporadic cases of QRNG infection had been reported in the continental United States [10] [11] [12] [13] .
The Centers for Disease Control and Prevention (CDC) recommends antibiotic treatment for gonorrhea that includes cephalosporins (cefixime and ceftriaxone) and fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin) [14] . According to the CDC, fluoroquinolone regimens can be used with confidence to treat gonorrhea, as long as QRNG strains constitute !1% of isolated gonococcal strains [15] . In 1999, the prevalence of QRNG was !0.5% nationwide [16] .
From July through September 2000, six QRNG cases were identified at a sexually transmitted diseases (STD) clinic in Orange County, California, an increase in prevalence from the previous 5 years, during which only 1 case had been identified at this clinic [17] . To identify risk factors for infection, to monitor the prevalence of QRNG, and to develop evidence-based gonorrhea treatment recommendations for California, a multiple-phase investigation was launched.
METHODS

Gonococcal Isolate Surveillance Project (GISP).
GISP is the US national surveillance system established in 1986 to monitor gonococcal resistance. As part of GISP, sentinel site STD clinics in northern California (San Francisco) and southern California (Long Beach, Orange County, and San Diego) submit up to 25 gonococcal isolates recovered from male urethral culture specimens each month. Antimicrobial susceptibility testing is performed by GISP Regional Laboratories, and the results are confirmed by the CDC using standard agar dilution methods [18] . Resistance to ciprofloxacin is defined as an MIC of у1.0 mg/ mL, intermediate resistance is defined as an MIC of 0.125-0.5 mg/mL, and susceptibility is defined as an MIC of р0.06 mg/ mL [19] . QRNG was defined as N. gonorrhoeae that is resistant to either ciprofloxacin or ofloxacin, according to nationally recognized susceptibility test interpretations [20, 21] .
Expanded antimicrobial resistance surveillance and case series, Southern California, January 2001 through June 2002. In addition to ongoing GISP surveillance in the southern California (Long Beach, Orange County, and San Diego) STD clinics, local public health laboratories in Orange County and San Diego conducted susceptibility testing of all gonococcal isolates from STD clinic patients, including isolates from women, from nonurethral sites, and in Orange County, from incarcerated patients. In addition, the Kaiser Permanente Southern California regional laboratory, which serves 190 clinic sites in 6 southern California counties (Kern, Los Angeles, Orange, Riverside, San Bernardino, and San Diego counties) tested all gonococcal isolates submitted during the period of February through April 2001. Disk diffusion methods were used to determine susceptibility to ciprofloxacin by the Orange County public health and Kaiser Permanente Southern California regional laboratories and to determine susceptibility to ofloxacin by the San Diego County public health laboratory [20, 21] . Fluoroquinolone resistance was confirmed by subsequent testing at a GISP Regional Laboratory using agar dilution methods described above. Patients infected with QRNG were interviewed in person or via telephone by trained disease investigators. Demographic characteristics, medical and STD history, and symptom data were abstracted from medical records.
Cross-sectional study, Northern and Southern California, July 2001 through June 2002. To determine the prevalence of QRNG infection among different risk groups and risk factors for acquisition of QRNG infection, we conducted a medical record review of male and female patients with viable gonococcal isolates from any anatomic site tested for fluoroquinolone resistance at any of the 4 California GISP STD clinics (in Long Beach, Orange County, San Diego, and San Francisco) during the period of July 2001 through June 2002. The San Francisco GISP site (in northern California) was included to determine whether the prevalence of and risk factors for QRNG infection differed across the state.
Statistical methods. All data were analyzed using SAS statistical software (SAS Institute) [22] . Men who reported having only male sex partners or having both male and female sex partners were categorized as men who have sex with men (MSM); men who reported having only female sex partners were categorized as men who have sex with women only (MSW). Fisher's exact tests were used to calculate P values, and standard asymptotic methods were used to calculate 95% CIs.
For the cross-sectional data analysis, prevalence ratios (PRs) were calculated to compare different demographic and risk categories with regard to the prevalence of QRNG infection. To control for possible confounding or effect-modifying factors, a logistic regression model using backward stepwise elimination was created. The model was restricted to male subjects and included the following variables: GISP clinic site, age, race/ ethnicity (white, Asian/Pacific Islander, or other), sexual orientation, HIV infection status, whether there had been multiple partners in prior 6 months, symptoms at site of infection, antibiotic use in prior month, commercial sex exposure, and injection drug use, as well as an interaction term between sexual orientation and clinic. Female subjects were excluded because no cases of QRNG infection were reported from 2 clinics, and travel history was excluded because data on it were reliably collected at only 1 test site (San Diego). Separate models for MSM and MSW were also created with the same set of variables to determine independent risk factors within these groups.
As disease control and surveillance activities, the components of this investigation were determined by CDC to be nonresearch public health activities that did not require approval from the CDC's Institutional Review Board.
RESULTS
After a peak rate of 445 cases of gonorrhea per 100,000 persons in California in 1985, the number of gonorrhea cases steadily decreased, to a nadir of 55.5 cases per 100,000 persons in 1997. Sixty-two case patients with QRNG infection (94%) were male; the median age was 32.5 years (range, 18-62 years). Thirty-nine patients were non-Hispanic white, 13 were Hispanic, 5 were Asian/Pacific Islander, 6 were African American, and 3 had other or unknown race. Forty patients (61%) were born in the United States; the regions of origin for non-USborn patients included Central/South America, Asia, Europe, and Canada. Among the 62 men, 48 (77%) reported that they had sex with men only, 7 (11%) reported that they had sex with women only, 5 (8.1%) reported that they had both male and female sex partners, and 2 refused to disclose this information. All 4 female case patients reported that they had male sex partners.
Antibiotic use within the 3 months before diagnosis of gonorrhea was reported by 29% of patients with QRNG; 6 patients reported that they had taken fluoroquinolones. Travel outside of the continental United States within 3 months before gonorrhea diagnosis was reported by 40% of case patients. Eighty percent of subjects reported that they had multiple sex partners in the prior 6 months. Although commercial sex exposure was reported by only 4 case patients, 1 patient was an MSM sex worker identified in San Diego in September 2001 who reported that he had 140 partners in the previous 3 months. Among the 43 patients with data on HIV infection, 16 (37%) were HIV positive, all of whom were MSM.
Cross-sectional study. 61 (7) 37 (16) 100 (14) 152 (7) 350 (9.7)
Race/ethnicity White 70 (11) 30 (17) 181 (14) 142 (2) 423 (9.9) Hispanic 108 (4) 25 (12) 47 (2) 25 (12) (7) 50 (18) 220 (14) 198 (2) 606 (8.6) MSW 69 (7) 58 (3) 87 (2) 79 (8) NOTE. Data are no. of patients tested (% infected with QRNG). Data on 6 persons were excluded (4 men were missing information on sexual orientation, and 2 subjects were male-to-female transgender persons). MSM, men who have sex with men; MSW, men who have sex with women only; WSM, women who have sex with men.
a More than 1 partner in the previous 6 months. b Exposure in previous 6-12 months. c Exposure in previous month. d Symptoms at site of infection (e.g., urethral discharge or dysuria in a patient with urethral infection). Patients with no symptoms and those who presented with symptoms at an anatomic site determined not to be infected were considered to not have symptoms. Groups with increased prevalence of QRNG varied among the different GISP sites. Unlike the southern California clinic sites, the prevalence of QRNG was low among white patients in San Francisco. At both San Diego and Long Beach, the prevalence was higher among MSM than among MSW (P p and , respectively), whereas MSM and MSW had .003 P p .02 a similar prevalence in Orange County. In San Francisco, MSW had higher prevalence than MSM ( ). Most clinic sites P p .03 had higher QRNG prevalence among HIV-infected patients, patients who reported antibiotic use in the prior month, patients who reported commercial sex exposure in the prior 6-12 months, patients who reported injection drug use in the prior 6-12 months, and patients who lacked symptoms at the site of infection, although the number of patients with any of these risk factors was small in any individual clinic.
Factors that were positively associated with QRNG in univariate analysis included attendance at the Long Beach or San Diego STD clinic (compared with San Francisco), age of у35 years, HIV infection, and antibiotic use within the prior month (table 2) . Compared with white patients, persons of other race/ ethnicity (primarily black and Hispanic patients) had a significantly lower prevalence of QRNG infection. Additional factors that were associated with QRNG but that did not reach statistical significance included MSM sexual orientation, commercial sex exposure, travel outside of the continental United States or to Hawaii, injection drug use, and lack of symptoms. When this analysis was repeated excluding from the denominator persons with gonococcal isolates with intermediate susceptibility to fluoroquinolones, there were only minor differences in the calculated PRs and no important differences in statistical associations.
Findings from the multivariate modeling are shown in table 3. Because of the highly significant interaction term between sexual orientation and clinic, MSM OR estimates for each clinic with the reference category being MSW from the same clinic are presented separately. Antibiotic use within the prior month was strongly associated with QRNG, as was MSM status (compared with MSW status) at the San Diego clinic. The association of QRNG with MSM at the Long Beach clinic was strong and nearly reached statistical significance. In contrast, MSM at the San Francisco clinic were at significantly decreased risk for acquisition of QRNG infection. There was also an increased risk of QRNG infection among persons of Asian race/ethnicity and a decreased risk among persons of other race/ethnicity, compared with white patients. , QRNG infection appeared to be widespread among MSM in southern California. These conclusions were supported by strain typing and molecular analysis of California QRNG isolates from 2000-2002, in which investigators found that, although there were 120 different type designations, more than one-half of the isolates belonged to the same outbreak strain, three-quarters of which were recovered from MSM, including the sex worker in San Diego [24] . On the basis of GISP surveillance through 2003, QRNG continued to increase among both MSM and heterosexuals in California.
Our finding that MSM in some southern California STD clinics were at increased risk of acquiring QRNG infection is consistent with published reports from other parts of the United States [25, 26] and the United Kingdom [27] [28] [29] . Of note, 2001 data from Hawaii demonstrated that heterosexuals were at increased risk of acquiring QRNG infection, compared with MSM [30] . These geographic and temporal differences are likely related to the role that different sexual networks play in the spread of STDs at different times and in different places.
Overuse of antibiotics has been implicated in increasing rates of antimicrobial resistance [31] . In our population, recent antibiotic use was associated with QRNG; however, only a minority of patients reported fluoroquinolone use. Similar associations with tetracycline, penicillin, and fluoroquinolone resistance have been identified in the United States and The Philippines [32] [33] [34] ; however, other risk analyses have not demonstrated this association [30, [35] [36] [37] [38] [39] . The process of developing resistance is multifactorial, and antimicrobials used to treat infections other than STDs may well have a larger role in causing resistance in N. gonorrhoeae than does use of antimicrobials for gonococcal infection. Thus, the overuse of antibiotics continues to be a concern in the development of antimicrobial-resistant organisms.
Changes over time in the epidemiology of antimicrobialresistant N. gonorrhoeae are not uncommon. When the prevalence of QRNG began to increase in Hawaii in 1999, most case patients reported foreign travel [9] . As the epidemic evolved, travel history was no longer a significant risk factor, probably reflecting endemic transmission of QRNG in the population [30, 40, 41] . A similar evolution occurred in London, England, between 1997 and 2000 [42] . These epidemiologic changes necessitate continuous monitoring to ensure appropriate interventions and treatment recommendations.
The documented high rates of QRNG infection led the California Department of Health Services and the CDC to issue new guidelines for treating gonorrhea acquired in California [40, 43] . First-line treatment is now limited to 1 class of drug, cephalosporins, although alternatives include spectinomycin and azithromycin at the 2-g dose. Sentinel surveillance has identified no important resistance to cephalosporins in the United States [44] . Treatment guidelines for California did not differentiate by sexual orientation for several reasons: (1) certain populations (e.g., women and young African American persons) were not adequately sampled, even with expanded surveillance; (2) recommendation simplicity increases provider compliance; and (3) our investigation provided evidence that risk factors change in a relatively short time as QRNG strains spread into different populations.
Health care providers in other parts of the country should ask patients with gonorrhea whether they or their sex partners could have acquired the infection in an area with high rates of QRNG (e.g., California, Hawaii, other Pacific Islands, Asia, United Kingdom, or other areas with emerging endemic QRNG). Recently, the CDC recommended cephalosporins as first-line treatment for MSM with gonorrhea [26] . These new recommendations highlight the importance of ascertaining the sex of sex partners. Clinicians should remain alert to treatment failures and counsel patients to return for additional treatment if symptoms persist or recur.
There were several limitations to these investigations. First, the prevalence of and risk factors for QRNG infection in STD clinic patients with gonorrhea may not be generalizable to all patients with gonorrhea. Compared with the demographic characteristics of patients with gonorrhea throughout the state, patients with gonococcal isolates that have undergone susceptibility testing were more likely to be male, older, and nonHispanic white race [40, 45] . Furthermore, STD clinic populations in California overrepresent MSM patients [46] . Second, small numbers of QRNG cases limited our power to detect risk factors, especially by clinic. Third, medical record data often are incomplete. In particular, travel history was generally not recorded-and perhaps not even assessed-despite current recommendations. Travel is a risk factor only when it involves sexual exposure to a person with QRNG; thus, better data are needed for precise interpretation.
With rates of QRNG infection increasing across the United States, continued surveillance and assessment of risk factors is critical to ensure a timely and effective public health response. Public health laboratories need to be supported in maintaining the capacity to culture gonorrhea and to perform antimicrobial susceptibility testing. Rapid dissemination of new treatment recommendations to clinicians is essential. Although high-level resistance to ceftriaxone and treatment failure has not been identified among N. gonorrhoeae isolates in the United States [44] , the emergence of multidrug-resistant N. gonorrhoeae has been reported [47] . Furthermore, reports from China indicate the sporadic occurrence of gonococcal isolates with decreased susceptibility to ceftriaxone [48, 49] . The eventual importation and endemic spread of these strains necessitates continued research and development of new antimicrobials and research on drug efficacy for the treatment of gonorrhea.
